Economic analysis of bevacizumab, cetuximab, and panitumumab with fluoropyrimidine-based chemotherapy in the first-line treatment of KRAS wild-type metastatic colorectal cancer (mCRC)

Journal of Medical Economics

Volumn 16, Issue 12, 2013, Pages 1387-1398

  Lawrence, Donna ^a   Maschio, Michael ^a   Leahy, Kevin J ^a   Yunger, Simon ^b   Easaw, Jacob C ^c   Weinstein, Milton C ^d  

^a OPTUM   (United States)

^b Hoffmann La Roche Ltd   (Canada)

^c TOM BAKER CANCER CENTRE   (Canada)

^d HARVARD SCHOOL OF PUBLIC HEALTH   (United States)

Author keywords

Bevacizumab; Cost effectiveness; First line treatment; Health economics; Metastatic colorectal cancer

Indexed keywords

BEVACIZUMAB; CETUXIMAB; FLUOROURACIL; FOLINIC ACID; IRINOTECAN; K RAS PROTEIN; OXALIPLATIN; PANITUMUMAB;

ADVERSE OUTCOME; ARTICLE; CANCER COMBINATION CHEMOTHERAPY; COST EFFECTIVENESS ANALYSIS; DIARRHEA; DRUG COST; HUMAN; HYPERTENSION; HYPOMAGNESEMIA; INJECTION SITE REACTION; METASTATIC COLORECTAL CANCER; OVERALL SURVIVAL; PROGRESSION FREE SURVIVAL; QUALITY ADJUSTED LIFE YEAR; RASH; STOMACH PERFORATION; THROMBOEMBOLISM;

ANGIOGENESIS INHIBITORS; ANTIBODIES, MONOCLONAL; ANTIBODIES, MONOCLONAL, HUMANIZED; ANTINEOPLASTIC AGENTS; CANADA; COLORECTAL NEOPLASMS; COST OF ILLNESS; COST-BENEFIT ANALYSIS; FEMALE; HUMANS; MALE; MARKOV CHAINS; MIDDLE AGED; MODELS, ECONOMIC; PROTO-ONCOGENE PROTEINS; QUALITY-ADJUSTED LIFE YEARS; RAS PROTEINS; RECEPTOR, EPIDERMAL GROWTH FACTOR;

EID: 84889825552     PISSN: 13696998     EISSN: 1941837X     Source Type: Journal    
DOI: 10.3111/13696998.2013.852097     Document Type: Article

References (33)

1. Advisory Committee on Cancer Statistics. Canadian Cancer Statistics 2013. Toronto, ON: Canadian Cancer Society, 2013. http://www.cancer.ca/en/ cancer-information/cancer-type/colorectal/statistics/. Accessed June 2013
2. Canadian Cancer Society's Steering Committee on Cancer Statistics. Canadian Cancer Statistics 2011. Toronto, ON: Canadian Cancer Society, 2011
3. Howlader N, Noone AM, Krapcho M, et al. SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD: National Cancer Institute. http://seer.cancer.gov/csr/19752009pops09/, based on November 2011 SEER data submission, posted to the SEER website, 2012. Accessed August 2013
4. Benson AB 3rd, Bekaii-Saab T, Chan E, et al. Metastatic colon cancer, version .2013: Featured updates to the NCCN Guidelines. J Natl Compr Canc Netw 2013;11:141-52
5. Jonker D, Biagi J, Haynes AE. The use of epidermal growth factor receptor inhibitors in advanced colorectal cancer. Toronto (ON): Cancer Care Ontario; 2008 Jul 9 [Archived 2012]. Program in Evidence-based Care CED-CCO Special Advice Report No.: 8 Archived British Columbia Cancer Agency. Cancer Management Guidelines: Colon. Treatment Options by Stage Based on Current Evidence. Revised 05 Sept 2012 Available at: Http://www.bccancer.bc.ca/HPI/Cancer ManagementGuidelines/Gastrointestinal/05.Colon/5.6+Treatment+Options +by+Stage+Based+on+Current+Evidence.htm. [Last accessed August 2013]
6. Presta LG, Chen H, O'Connor SJ, et al. Humanization of an anti-vascular endothelial growth factor monoclonal antibody for the therapy of solid tumors and other disorders. Cancer Res 1997;57:4593-9
7. Kim KJ, Li B, Winer J, et al. Inhibition of vascular endothelial growth factorinduced angiogenesis suppresses tumour growth in vivo. Nature 1993;362:841-4
8. Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. NEJM 2004;350:2335-42
9. Van Cutsem E, Koddddhne CH, Lá ng I, et al. Cetuximab plus irinotecan, fluorouracil, and leucovorin as first-line treatment for metastatic colorectal cancer: Updated analysis of overall survival according to tumor KRAS and BRAF mutation status. J Clin Oncol 2011;29:2011-9
10. Douillard JY, Siena S, Cassidy J, et al. Randomized, phase III trial of panitumumab with infusional fluorouracil, leucovorin, and oxaliplatin (FOLFOX4) versus FOLFOX4 alone as first-line treatment in patients with previously untreated metastatic colorectal cancer: The PRIME study. J Clin Oncol 2010;28:4697-705
11. ImClone LLC. Erbitux Product Monograph. 2012
12. Hurwitz H, Yi J, Ince W, et al. The clinical benefit of bevacizumab in metastatic colorectal cancer is independent of K-ras mutation status: Analysis of a phase III study of bevacizumab with chemotherapy in previously untreated metastatic colorectal cancer. Oncologist 2009;14:22-8
13. Song X, Zhao Z, Barber B, et al. Cost of illness in patients with metastatic colorectal cancer. J Med Econ 2011;14:1-9
14. Canadian Agency for Drugs and Technologies in Health. Guidelines for the economic evaluation of health technologies: Canada. 3rd edn. Ottawa: Government of Canada, 2006
15. Gold MR, Siegel JE, Russell LB, et al. Cost-effectiveness in health and medicine. New York: Oxford University Press, 1996
16. Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: A randomized GERCOR study. J Clin Oncol 2004;22:229-37
17. Fuchs CS, Marshall J, Mitchell E, et al. Randomized, controlled trial of irinotecan plus infusional, bolus, or oral fluoropyrimidines in first-line treatment of metastatic colorectal cancer: Results from the BICC-C Study. J Clin Oncol 2007;25:4779-86
18. Kaplan EL, Meier PL. Nonparametric estimation from incomplete observations. J Am Statist Assoc 1958;56:457-81
19. Statistics Canada. CANSIM Table 326-0021. Consumer Price Index (CPI), 2009 basket. Ottawa: Government of Canada, 2013. Available at: Http:// www5.statcan.gc.ca/cansim/a26?lang=eng&retrLang=eng&id=3260021& pattern=326-0020.326-0022&tabMode=dataTable&srchLan=-1&p1=-1& p2=31. [Last accessed 20 February 2012]
20. Cancer Care Ontario. Cancer Care Ontario Drug Formulary. 2011. Available at: Https://www.cancercare.on.ca/toolbox/drugs/drugformulary/. [Last accessed November 2011]
21. British Columbia Cancer Agency. Chemotherapy Protocols: Gastrointestinal. 2011. Available at: Http://www.bccancer.bc.ca/HPI/ChemotherapyProtocols/ default.htm. [Last accessed November 2011]
22. Dranitsaris G, Truter I, Lubbe MS, et al. The application of pharmacoeconomic modelling to estimate a value-based price for new cancer drugs. J Eval Clin Pract 2012;18:343-51
23. Hoffmann-La Roche Limited. Data on file. 2012
24. Hoffmann-La Roche Limited. Avastin Product Monograph. 2012
25. Ontario Ministry of Health and Long-Term Care. Ontario Drug Benefit Formulary/Comparative Drug Index. 2012. Available at: www.healthinfo. moh.gov.on.ca/formulary/index.jsp. [Last accessed January 2012]
26. Ré gie de l'assurance maladie du Qué bec. List of Medications. Last Updated on 16 December 2011. Available at: www.prod.ramq.gouv.qc.ca. [Last accessed January 2012]
27. Ontario Case Costing Initiative. Ontario guide to case costing. Province of Ontario, Canada: Ministry of Health and Long-Term Care, 2012. Available at: www.occp.com/mainPage.htm. [Last accessed February 2012]
28. Ontario Ministry of Health and Long-Term Care. Schedule of Benefits: Physician Services under the Health Insurance Act. Ontario: 2012. Available at: www.health.gov.on.ca/english/providers/program/ohip/sob/ physserv/aconsul.pdf [Last accessed January 2012]
29. CanadaDrugs.com. 2012. Available at: www.canadadrugs.com. [Last accessed January 2012]
30. Bennouna J, Sastre J, Arnold D, et al. Continuation of bevacizumab after first progression in metastatic colorectal cancer (ML18147): A randomised phase 3 trial. Lancet Oncol 2013;14:29-37
31. Petrou S, Campbell N. Stabilisation in colorectal cancer. Int J Palliat Nurs 1997;3:275-80
32. SAS Institute Inc. SAS/STAT 9.2 User's Guide, Second Edition. The LIFETEST Procedure: Pointwise Confidence Limits in the OUTSURV= Data Set. Cary, NC: SAS Institute Inc. 2009. http://support.sas.com/documenta tion/cdl/en/statug/63033/HTML/default/viewer.htm#statuglifetesta00000 00262.htm. [Last accessed 14 June 2012]
33. Asseburg C, Frank M, Koddddhne CH, et al. Cost-effectiveness of targeted therapy with cetuximab in patients with K-ras wild-type colorectal cancer presenting with initially unresectable metastases limited to the liver in a German setting. Clin Ther 2011;33:482-97